Stoke Therapeutics Announces Presentations from the Company's Dravet Syndrome Program at the American Epilepsy Society 2021 Annual MeetingBusiness Wire • 11/19/21
Stoke Therapeutics to Present at the Cantor Global Healthcare Virtual ConferenceBusiness Wire • 09/22/21
Stoke Therapeutics Announces Positive Interim Safety, PK and CSF Exposure Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet SyndromeBusiness Wire • 09/21/21
Stoke Therapeutics to Present at the UBS Global Healthcare Virtual ConferenceBusiness Wire • 05/18/21
Stoke Therapeutics Presents New Data That Demonstrate Tango Antisense Oligonucleotides (ASOs) Increase OPA1 Protein Production and Improve Mitochondrial Function in Cells Derived From Patients With Autosomal Dominant Optic Atrophy (ADOA)Business Wire • 05/04/21
Stoke Therapeutics Announces MHRA Authorization to Initiate Phase 1/2a Clinical Trial of STK-001 for Dravet Syndrome in the United KingdomBusiness Wire • 03/30/21
Stoke Therapeutics Reports Full Year 2020 Financial Results and Provides Business UpdatesBusiness Wire • 03/09/21
Stoke Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/04/21
Stoke Therapeutics: A Preclinical Biopharma With A Multibillion Dollar Market CapSeeking Alpha • 12/14/20
Stoke Therapeutics to Present at the Needham Virtual Epilepsy & Pain – Specialty CNS Therapeutics ConferenceBusiness Wire • 12/04/20
Stoke Therapeutics Announces Presentations Related to the Company's Work to Advance STK-001, the First Potential New Medicine to Target the Underlying Cause of Dravet Syndrome at the American Epilepsy Society (AES) 2020 Annual MeetingBusiness Wire • 12/04/20
Notable Insider Buys in the Past Week: Biglari, Coty, Danaher, Foot Locker And MoreBenzinga • 11/28/20
Stoke Therapeutics Announces Presentations Related to the Company's Work in Dravet Syndrome at the American Epilepsy Society 2020 Virtual Annual MeetingBusiness Wire • 11/25/20
Stoke Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesBusiness Wire • 11/24/20
Stoke Therapeutics to Present at the Stifel 2020 Virtual Healthcare ConferenceBusiness Wire • 11/09/20
Stoke Therapeutics to Present at 29th Annual Credit Suisse Virtual Healthcare ConferenceBusiness Wire • 11/02/20
Stoke Therapeutics Announces Plans to Move Forward With Dosing of STK-001 in Children and Adolescents in its Ongoing Phase 1/2a MONARCH Study for Dravet SyndromeBusiness Wire • 10/07/20
Stoke Therapeutics Announces Publication of Preclinical Data on STK-001 in the Journal Science Translational Medicine that Demonstrate Significant Improvements in Survival and Reductions in Seizure Frequency in a Dravet Syndrome Mouse ModelBusiness Wire • 08/26/20